Last reviewed · How we verify

NCT07261956

Lung Ultrasound for the Detection of Volume Overload in Patients With Severe Preeclampsia

Recruiting now NA Last updated 3 December 2025
What this trial tests

NA trial testing Lung ultrasound in Pulmonary Edema - Acute in 202 participants. Currently enrolling.

Timeline
25 August 2025
Primary endpoint
31 December 2025
31 January 2026

Quick facts

Lead sponsorSaint Thomas Hospital, Panama
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment202
Start date25 August 2025
Primary completion31 December 2025
Estimated completion31 January 2026
Sites1 location across Panama

Drugs / interventions tested

Conditions studied

Sponsor

Saint Thomas Hospital, Panama

Who can join

Eligibility, female only, with Pulmonary Edema - Acute or Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research aims to evaluate the usefulness of lung ultrasound (LUS) for detecting and monitoring fluid overload in patients with severe preeclampsia. Severe preeclampsia is a leading cause of maternal death and illness worldwide, often causing fluid buildup that can lead to a serious complication called pulmonary edema, especially after delivery. The study will be a prospective, longitudinal observational study with a diagnostic validation component. It will involve patients with a diagnosis of severe preeclampsia who meet specific inclusion criteria. Each participant will undergo a clinical exam and a lung ultrasound, which will assess eight zones of the lungs. The total number of B-lines-a sign of interstitial edema-will be documented. Data will be collected at three key times: upon admission, in the immediate postpartum period (within 24 hours of delivery), and 7-10 days postpartum. The results from the LUS will be compared to clinical signs like shortness of breath, rapid breathing, crackling sounds in the lungs, and oxygen saturation levels. The expected impact of this research is to provide evidence that LUS is a valuable, non-invasive, and accessible tool for the early detection of pulmonary congestion in patients with severe preeclampsia. This could lead to improved clinical decision-making and a reduction in maternal respiratory complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lung ultrasound

Trials testing the same drug.

Other Saint Thomas Hospital, Panama trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07261956.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing